


2

Docket No. ARYX-116XC1
Serial No. 10/624,659In the Claims

This listing of claims will replace all prior versions and listings of claims in this application.

Claim 1 (Cancel).


Claim 2 (currently amended). ~~The~~ An inhibitor of HMG-CoA reductase, ~~according to claim~~
1, having a structure selected from the group consisting of:



3

Docket No. ARYX-116XC1

Serial No. 10/624,659




and salts thereof.

4

Docket No. ARYX-116XC1

Serial No. 10/624,659

Claim 3 (currently amended). The compound, according to claim 1, wherein said compound has a structure selected from the group consisting of:




and salts thereof.

5

Docket No. ARYX-116XC1

Serial No. 10/624,659

Claim 4 (currently amended). The compound, according to claim 1, wherein said compound has a structure selected from the group consisting of:




and salts thereof.

6















Docket No. ARYX-116XC1
Serial No. 10/624,659

Claim 5 (Cancel).

Claim 6 (currently amended). ~~The A~~ pharmaceutical composition, ~~according to claim 5,~~
wherein said composition comprises a pharmaceutical carrier and a compound ~~has~~ having a structure
selected from the group consisting of:



7


Docket No. ARYX-116XC1
Serial No. 10/624,659

and salts thereof.

8

Docket No. ARYX-116XC1
Serial No. 10/624,659

Claim 7 (currently amended). The pharmaceutical composition, according to claim 5_6, wherein said compound has a structure selected from the group consisting of:




and salts thereof.

9

Docket No. ARYX-116XC1

Serial No. 10/624,659

Claim 8 (currently amended): The pharmaceutical composition, according to claim 5, wherein said compound has a structure selected from the group consisting of:




and salts thereof.

10

Docket No. ARYX-116XC1
Serial No. 10/624,659

Claim 9 (Cancel).


Claim 10 (currently amended). ~~The method, according to claim 9, A method for inhibiting HMG-CoA reductase in an individual in need of such treatment wherein said method comprises administering to said individual a compound~~ wherein said compound has a structure selected from the group consisting of:



11

Docket No. ARYX-116XC1

Serial No. 10/624,659




and salts thereof.

12

Docket No. ARYX-116XC1
Serial No. 10/624,659

Claim 11 (currently amended): The method, according to claim 9 10, wherein said compound has a structure selected from the group consisting of:




and salts thereof.

13

Docket No. ARYX-116XC1
Serial No. 10/624,659

Claim 12 (currently amended). The method, according to claim [9] 10, wherein said compound has a structure selected from the group consisting of:



14

Docket No. ARYX-116XC1
Serial No. 10/624,659

Claim 13 (currently amended). The method, according to claim 9 10, wherein the individual is a human.

Claim 14 (currently amended): The method, according to claim 9 10, wherein said method is used to lower cholesterol levels.